跳至主要内容
临床试验/NCT00583440
NCT00583440已完成1 期

12-step Facilitation for the Dually Diagnosed

University of New Mexico2 个研究点 分布在 1 个国家目标入组 121 人开始时间: 2005年9月最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
121
试验地点
2
主要终点
Percent days abstinent from alcohol

研究概览

简要总结

This is a randomized trial testing the efficacy of a modified 12-step facilitation therapy for individuals with serious mental illness and alcohol use disorders, compared to usual treatment. 135 participants are randomized in 2:1 ratio to the modified 12-step facilitation (12 sessions of individual counseling) vs. treatment as usual. The primary hypothesis is that those receiving 12-step facilitation will have better drinking outcomes (percent days abstinence and drinks per drinking day)at end of treatment.

详细描述

Although there has been relatively little work on 12-step treatment for seriously mentally ill patients, extant literature indicates that dually diagnosed individuals attend traditional 12-step programs such as AA, NA, and CA at rates comparable to singly diagnosed substance abusers, and that participation is associated with decreases in substance use. Specialized 12-step programs for the dually diagnosed, developed over the past 10 years, may offer additional benefits. In order to maximize the effectiveness of specialized and traditional 12-step programs for dually diagnosed individuals, specially adapted 12-step facilitation (TSF) treatment for the dually diagnosed should be developed and tested. Standard TSF should be modified to address the special needs of dually diagnosed individuals, mesh with specialized 12-step programs available in the area, and address barriers to attendance, participation, and engagement experienced by the dually diagnosed. We have developed a modified TSF based on the Project MATCH TSF manual. Modifications to this 12 week individual therapy include: emphasis on specialized 12-step program attendance; readings primarily from specialized 12-step program literature; participation in the second session by a community specialized 12-step program member; case management to assist participants in finding and attending meetings; omission of work on the fourth step; and the addition of topics covering medication compliance and specific social skills needed to negotiate 12-step meetings. In a pilot study with 10 dually diagnosed individuals, participants showed significant decreases in substance use and significant increases in 12-step attendance after receiving the specialized TSF. Building on this pilot study, the proposed study is a larger Stage 1b study of the modified TSF for seriously mentally ill patients engaged in dual diagnosis treatment. Participants with a psychotic or major affective disorder will be randomized to modified TSF (n=90) vs. treatment as usual (n=45). Participants will be followed for a total of 48 weeks. Assessments will include rigorous diagnosis and measures of alcohol and other drug use, consequences, psychiatric symptoms, 12-step behaviors, 12-step specific and non-specific change mechanisms, and social support. Specific Aims of the study include assessment of the integrity of the planned intervention and assessment battery; tests of the effectiveness of the adapted TSF relative to treatment as usual; determination of whether psychiatric diagnosis moderates treatment response; and investigation of causal mechanisms of response to treatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • SCID Diagnosis of a psychotic disorder (schizophrenia, schizoaffective disorder, or psychosis not otherwise specified) or a major affective disorder (major depression, bipolar disorder, or depressive disorder not otherwise specified, provided in the latter case that criteria have been met for a major depressive episode).
  • SCID diagnosis of alcohol abuse or dependence which is active within the past 1 month (i.e., not in early or sustained full remission).
  • Two or more days of heavy drinking (5 or more drinks for per occasion for a man, 4 or more drinks per occasion for a woman) in the 30 days prior to screening.
  • Willingness to participate in specialized 12-step programs.
  • Ability to provide informed consent.
  • Ability to read, speak, and understand English at least the 5th grade level.
  • Ability to provide at least one contact person to assist in tracking for follow-up assessment.

排除标准

  • Current attendance of any 12-step program (two or more 12-step meetings in the past month).
  • Unstable psychiatric illness, defined by psychiatric hospitalization in the past 1 month; more than 3 hospitalizations in the past year; or psychosis or mania which would render the individual incapable of informed consent.
  • Active suicidality (any clinically significant suicide attempts in the past 3 months or any current suicidal intent or definite plan).
  • Current homicidal ideation aimed at a specific person or persons.
  • Medical illness which is severe enough to compromise participation in the study.
  • Mental retardation, dementia, or other cognitive impairment of sufficient severely to render the individual incapable of informed consent or incapable of comprehending and participating in the TSF therapy or 12-step meetings.
  • Expectation of being out of town or in jail for more than 21 days during the treatment period.
  • Expectation of participation in any other formal addiction treatment during the study period (not including TAU, 12-step or other mutual support groups).
  • Current engagement in behavioral health treatment (including case management) at another facility.
  • Current engagement in non-TAU treatment at UNMPC, such as psychotherapy, intensive outpatient treatment, or MET.

结局指标

主要结局

Percent days abstinent from alcohol

时间窗: 12, 24, 36, and 48 weeks

次要结局

  • Drinks per drinking day(12, 24, 36, and 48 weeks)
  • 12-step participation(12, 24, 36, and 48 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Michael Bogenschutz

Professor of Psychiatry

University of New Mexico

研究点 (2)

Loading locations...

相似试验

已完成
4 期
Detrol LA In Men With Overactive Bladder.Overactive Bladder (OAB)
NCT00282932Pfizer's Upjohn has merged with Mylan to form Viatris Inc.600
已完成
不适用
Breathe Easier II: A Dyad-based Multiple Behavior InterventionLung Cancer, Nonsmall CellCOPDSelf-ManagementPhysical InactivityStressQuality of Life
NCT05956782University of South Carolina40
进行中(未招募)
2 期
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic AgentsFallopian Tube Mucinous AdenocarcinomaOvarian Seromucinous CarcinomaPlatinum-Refractory Fallopian Tube CarcinomaPlatinum-Refractory Ovarian CarcinomaPlatinum-Refractory Primary Peritoneal CarcinomaRecurrent Fallopian Tube Clear Cell AdenocarcinomaRecurrent Fallopian Tube Endometrioid AdenocarcinomaRecurrent Fallopian Tube High Grade Serous AdenocarcinomaRecurrent Fallopian Tube Mucinous AdenocarcinomaRecurrent Fallopian Tube Transitional Cell CarcinomaRecurrent Fallopian Tube Undifferentiated CarcinomaRecurrent Low Grade Fallopian Tube Serous AdenocarcinomaRecurrent Ovarian Clear Cell AdenocarcinomaRecurrent Ovarian Endometrioid AdenocarcinomaRecurrent Ovarian High Grade Serous AdenocarcinomaRecurrent Ovarian Low Grade Serous AdenocarcinomaRecurrent Ovarian Mucinous AdenocarcinomaRecurrent Ovarian Seromucinous CarcinomaRecurrent Ovarian Transitional Cell CarcinomaRecurrent Ovarian Undifferentiated CarcinomaRecurrent Platinum-Resistant Fallopian Tube CarcinomaRecurrent Platinum-Resistant Ovarian CarcinomaRecurrent Platinum-Resistant Primary Peritoneal CarcinomaRecurrent Primary Peritoneal Clear Cell AdenocarcinomaRecurrent Primary Peritoneal Endometrioid AdenocarcinomaRecurrent Primary Peritoneal High Grade Serous AdenocarcinomaRecurrent Primary Peritoneal Low Grade Serous AdenocarcinomaRecurrent Primary Peritoneal Transitional Cell CarcinomaRecurrent Primary Peritoneal Undifferentiated CarcinomaRefractory Fallopian Tube Clear Cell AdenocarcinomaRefractory Fallopian Tube Endometrioid AdenocarcinomaRefractory Fallopian Tube High Grade Serous AdenocarcinomaRefractory Fallopian Tube Mucinous AdenocarcinomaRefractory Fallopian Tube Transitional Cell CarcinomaRefractory Fallopian Tube Undifferentiated CarcinomaRefractory Low Grade Fallopian Tube Serous AdenocarcinomaRefractory Ovarian Clear Cell AdenocarcinomaRefractory Ovarian Endometrioid AdenocarcinomaRefractory Ovarian High Grade Serous AdenocarcinomaRefractory Ovarian Low Grade Serous AdenocarcinomaRefractory Ovarian Mucinous AdenocarcinomaRefractory Ovarian Seromucinous CarcinomaRefractory Ovarian Transitional Cell CarcinomaRefractory Ovarian Undifferentiated CarcinomaRefractory Primary Peritoneal Clear Cell AdenocarcinomaRefractory Primary Peritoneal Endometrioid AdenocarcinomaRefractory Primary Peritoneal High Grade Serous AdenocarcinomaRefractory Primary Peritoneal Low Grade Serous AdenocarcinomaRefractory Primary Peritoneal Transitional Cell CarcinomaRefractory Primary Peritoneal Undifferentiated Carcinoma
NCT04739800National Cancer Institute (NCI)120
尚未招募
不适用
Levels of Diagnostic and Therapeutic Intervention in Hospitalized PatientsAcute Disease
NCT06315842Consorci Sanitari de l'Alt Penedès i Garraf20
已完成
不适用
Is intranasal fentanyl no worse than intravenous morphine in the treatment of painful sickle cell crisis in the paediatric emergency department?Painful sickle cell crisisHaematological DisordersSickle-cell anaemia with crisis
ISRCTN67469672niversity College Dublin (Ireland)31